Chek the Channels
Meet 125 Mgmt Teams
Dyadic International Inc. (DYAI)
Progress and Efforts Continues to Validate C1 Platform
Dyadic International Inc. is a biotechnology company developing a proprietary C1 expression platform to express and manufacture biologic products. The C1 technology is part of a fungi expression system, which utilizes inexpensive substrates yielding a high level of production. Dyadic is currently improving and optimizing the production of biological products in a C1 expression system. The company’s partnership portfolio with pharmaceutical and institutions includes Zapi Project, Israel Institute for Biological Research, Mitsubishi Tanabe Pharma, Sanofi-Aventis covering the production of a diverse range of biologics, such as monoclonal antibodies, bispecific and Fc-fusion proteins. Dyadic also established a sub-licensing agreement with an Australian based drug development and contract manufacturing firm, Luina Bio, to utilize C1 platform for the development and commercialization of biological products to prevent and treat animal diseases. Company’s C1 bioenergy business was sold to Dupond Industrial Biosciences (DuPont) for $75 mm in 2015 granting the company the rights to use C1 platform in biopharma applications.
Ahu Demir, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Dyadic is progressing towards generating human-like glycosylation by C1 platform. Dyadic ’s research partner VTT Technical Research Centre of Finland made further progress in glycoengineering by expressing another human-like glycan (G2). The company currently generated two (G0 and G2) of the four targeted mammalian glycans (Exhibit 1).
Glycosylation is key in bioproduction. Glycosylation refers to adding a carbohydrate to a protein. Majority of biologics (over 50%) are glycosylated including antibodies and cytokines. Glycans have marked effects on therapeutic efficacy, immunogenicity, protein stability, moderation of half-life of proteins. Therefore, glycoengineering is crucial in drug development. On the way to validate C1 technology in bioproduction, glycoengineering to produce...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.